- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joe O'Sullivan: We Are Getting Better at Treating Prostate Cancer Earlier
New therapies and imaging modalities have helped providers treat patients who have prostate cancer earlier, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Transcript
New therapies and imaging modalities have helped providers treat patients who have prostate cancer earlier, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Are we getting better at identifying patients with prostate cancer who are likely to relapse and who might need treatment intensification?
I think we are. I think the reason we are getting better at that is because now we have therapies for those patients. When I started treating prostate cancer, first, there really wasn’t a huge benefit in finding out early that somebody had metastasized, because all we had was castration therapy. Now that we have multiple therapies, and also now that we are also getting more ambitious with treatment like stereotactic radiotherapy for oligometastatic prostate cancer, there’s now good value in discovering recurrences at an earlier stage.
In tandem with that, as well as therapeutic research going well, we have a lot of new imaging modalities—whole body MRI, PSMA-PET scans—these are helping us to see a bit deeper inside the patient and maybe identify disease at an earlier stage when it might benefit from therapy.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
